Absolute and Relative Effectiveness of Cell Culture–Based and Egg–Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014–2015 to 2018–2019 Seasons, US Flu VE Network
Clinical Infectious Diseases · 02.09.2026 · 83 (2) · 289-302
DOI: 10.1093/cid/ciaf579 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 16.10.2025. Verfasst von Manjusha Gaglani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Vaccine Efficacy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCIRD CDC HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Background
Estimates of the annual effectiveness of influenza vaccination combine multiple vaccine types. Reports of brand/product-specific vaccine effectiveness (VE) of egg-based and cell culture–based quadrivalent inactivated influenza vaccines (IIV4 and ccIIV4, respectively) are limited.
Methods
Using an observational test-negative study design, we compared the effectiveness of selected IIV4 and ccIIV4 products among outpatients enrolled in the US Influenza Vaccine Effectiveness (Flu VE) Network from 2014–2015 to 2018–2019. We used multivariable logistic regression to estimate the product-specific and age group–specific absolute VE and relative VE (rVE) of recommended, age-appropriate vaccines against symptomatic laboratory-confirmed outpatient influenza. The rVE of ccIIV4 versus IIV4 products was estimated during 2 seasons from 2017–2019 among participants aged ≥4 years.
Results
Pooling data from 5 influenza seasons when 18% and 15% of vaccinated patients had received Fluarix Quadrivalent or Fluzone Quadrivalent IIV4, respectively, the VE against influenza was 32% for Fluarix and 37% for Fluzone. Pooling 2 seasons when 11% and 28% of vaccinated patients had received ccIIV4 (Flucelvax Quadrivalent) and IIV4 (FluLaval Quadrivalent), respectively, the VE against influenza for each product was 30%. The absolute VE compared with unvaccinated patients was lowest against influenza A(H3N2) compared with that against A(H1N1)pdm09 and each B lineage; VE point estimates were lowest among patients aged ≥50 years compared with 2 younger age groups. The rVE estimates were not statistically significant, indicating similar protection across vaccine products.
Conclusions
Comparisons of influenza vaccine products over multiple seasons showed benefit of both IIV4 and ccIIV4 against symptomatic laboratory-confirmed outpatient influenza, with similar absolute and relative levels of protection provided by each product.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.
- Department of Pediatrics, Baylor College of Medicine, Temple, Texas, USA.
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
- Department of Family Medicine, Schools of Health Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Epidemiology and Research, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
- Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
ORCID-Profile: Manjusha Gaglani, Kempapura Murthy, Briget da Graca, Gueorgui Dubrocq, Richard K Zimmerman, Huong Q Nguyen, Sara S Kim, Jessie R Chung
Förderung
- NCATS NIH HHS
- NCIRD CDC HHS
- NCRR NIH HHS
- Intramural CDC HHS
- US Centers for Disease Control and Prevention
- Baylor Scott & White Health
- Marshfield Clinic Research Institute
- Kaiser Permanente Washington Research Institute
Zitieren
APA
Gaglani, M., Raiyani, C., Murthy, K., Smith, M., da Graca, B., Dubrocq, G., Beeram, M., Martin, E. T., Monto, A. S., Zimmerman, R. K., Nowalk, M. P., Kiniry, E., Phillips, C. H., Nguyen, H. Q., King, J. P., Kim, S. S., Chung, J. R., & Flannery, B. (2026). Absolute and Relative Effectiveness of Cell Culture–Based and Egg–Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014–2015 to 2018–2019 Seasons, US Flu VE Network. Clinical Infectious Diseases, 83(2), 289-302. https://doi.org/10.1093/cid/ciaf579
Vancouver
Gaglani M, Raiyani C, Murthy K, Smith M, da Graca B, Dubrocq G, et al. Absolute and Relative Effectiveness of Cell Culture–Based and Egg–Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014–2015 to 2018–2019 Seasons, US Flu VE Network. Clinical Infectious Diseases. 2026;83(2):289-302. doi:10.1093/cid/ciaf579
BibTeX
@article{Gaglani2026,
author = {Gaglani, Manjusha and Raiyani, Chandni and Murthy, Kempapura and Smith, Michael and da Graca, Briget and Dubrocq, Gueorgui and Beeram, Madhava and Martin, Emily T and Monto, Arnold S and Zimmerman, Richard K and Nowalk, Mary Patricia and Kiniry, Erika and Phillips, C Hallie and Nguyen, Huong Q and King, Jennifer P and Kim, Sara S and Chung, Jessie R and Flannery, Brendan},
title = {Absolute and Relative Effectiveness of Cell Culture–Based and Egg–Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014–2015 to 2018–2019 Seasons, US Flu VE Network},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {83},
number = {2},
pages = {289--302},
doi = {10.1093/cid/ciaf579}
}
EUVIMED